Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379973 | 0.89 | ALDH1A1 (0.44) | ARRORCCYP2C19 | |
| SCHEMBL3289681 | 0.89 | AR (0.54) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL1378748 | 0.86 | RORC (0.49) | ARRORC | |
| SCHEMBL4207876 | 0.84 | CNR2 (0.53) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL3289604 | 0.84 | CNR2 (0.53) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL20459116 | 0.84 | AR (0.60) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL29328408 | 0.82 | AR (0.64) | ARRORCCYP2C19ABCB11ALB | |
| SCHEMBL25166923 | 0.81 | AR (0.55) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL30171209 | 0.81 | AR (0.63) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL22728020 | 0.81 | AR (0.63) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | claimed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | claimed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | claimed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR3C2, NR5A1 | AR 1/4885RORC 162/4885CYP2C19 201/4885 |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | AR, NR3C2, NR5A1 | AR 1/4885RORC 162/4885CYP2C19 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.